HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference NEW YORK and VIENNA, Austria, March 06, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...

HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs HOOKIPA to prioritize clinical development of HB-200 for the treatment of HPV16+ head and neck cancers and Gilead-partnered programs in infectious disease HOOKIPA will regain global development rights...

HOOKIPA Pharma Reports First Quarter 2023 Financial Results and Recent Business Highlights HOOKIPA on track to report Phase 2 data on HB-200 for head and neck cancer in combination with pembrolizumab in 2Q 2023Phase 1 clinical trials initiated for two programs (HB-300 for advanced prostate...

HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis B NEW YORK and VIENNA, Austria, May 09, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...

HOOKIPA announces strategic collaboration and license agreement with Roche to develop novel arenaviral immunotherapy for KRAS-mutated cancers Roche to receive license for HOOKIPA’s HB-700 program and option to license a second undisclosed novel arenaviral immunotherapyHOOKIPA to receive $25 million in upfront cash as well as potential...